Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bob T Li

Showing results (81-90 of 139) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre studyW Victoria Lai, Louisiane Lebas, Tristan A Barnes, et al.
Nature Medicine|July 18, 2017
An approach to suppress the evolution of resistance in BRAF<sup>V600E</sup>-mutant cancerYaohua Xue, Luciano Martelotto, Timour Baslan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Future Oncology (London, England)|November 27, 2023
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summaryGrace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
The New England Journal of Medicine|June 7, 2021
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C MutationFerdinandos Skoulidis, Bob T Li, Grace K Dy, et al.
Cancer|August 19, 2020
Clinical implications of drug-induced liver injury in early-phase oncology clinical trialsSebastian P Mondaca, Dazhi Liu, Jessica R Flynn, et al.
Investigational New Drugs|March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxelLillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2019
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic SarcomasNatasha Rekhtman, Joseph Montecalvo, Jason C Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2020
<i>MET</i> Exon 14-altered Lung Cancers and MET Inhibitor ResistanceRobin Guo, Michael Offin, A Rose Brannon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for InterventionNicolas A Giraldo, Esther Drill, Baby A Satravada, et al.
Pageof 14

Showing results (81-90 of 139) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre studyW Victoria Lai, Louisiane Lebas, Tristan A Barnes, et al.
Nature Medicine|July 18, 2017
An approach to suppress the evolution of resistance in BRAF<sup>V600E</sup>-mutant cancerYaohua Xue, Luciano Martelotto, Timour Baslan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
Future Oncology (London, England)|November 27, 2023
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summaryGrace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, et al.
The New England Journal of Medicine|June 7, 2021
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C MutationFerdinandos Skoulidis, Bob T Li, Grace K Dy, et al.
Cancer|August 19, 2020
Clinical implications of drug-induced liver injury in early-phase oncology clinical trialsSebastian P Mondaca, Dazhi Liu, Jessica R Flynn, et al.
Investigational New Drugs|March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxelLillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2019
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic SarcomasNatasha Rekhtman, Joseph Montecalvo, Jason C Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2020
<i>MET</i> Exon 14-altered Lung Cancers and MET Inhibitor ResistanceRobin Guo, Michael Offin, A Rose Brannon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for InterventionNicolas A Giraldo, Esther Drill, Baby A Satravada, et al.
Pageof 14